Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Chronic Insomnia Treated Effectively By Online Cognitive Behavioral Therapy
A study in the June 1 issue of the journal SLEEP demonstrates that online cognitive behavioral therapy (CBT) for chronic insomnia significantly improves insomnia severity, daytime fatigue, and sleep quality. Online treatment also reduces erroneous beliefs about sleep and pre-sleep mental arousal.
buy viagra
Take Steps To Learn From Child Medication Errors, MDU Urges GPS, UK
The Medical Defence Union (MDU) is reminding its GP members about the steps they can take to avoid medication errors when treating children and the importance of learning from errors. The advice follows the publication of the National Patient Safety Agency"s (NPSA) first review of patient safety incidents involving the under 18s reported under the national reporting and learning system (RLS).
News of the day
Spectrum Pharmaceuticals Receives Complete Response Letter From FDA For Zevalin
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental Biologics License Application (sBLA) for ZEVALIN® (ibritumomab tiuxetan) in the first-line consolidation setting for non-Hodgkin"s Lymphoma (NHL) patients. The Prescription Drug User Fee Act (PDUFA) Action Date for the ZEVALIN sBLA in the first-line consolidation setting was July 2, 2009. ZEVALIN is currently FDA approved and marketed by Spectrum for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients who have rituximab-refractory follicular NHL.
Public Health

"Gene Silencing" May Improve Treatment Of A Deadly Complication Of Liver Disease

A technique that "silences," or turns off, genes shows promise as a potential new treatment for liver fibrosis - the disease that leads to cirrhosis - scientists in Tennessee are reporting. Their study is scheduled for the June 1 issue of ACS" Molecular Pharmaceutics, a bi-monthly journal. Cirrhosis is the 12th leading cause of death in the United States. Ram Mahato and colleagues note that fibrosis involves build-up of scar tissue in the liver from chronic liver damage caused by hepatitis, alcohol abuse, toxins, or other factors. Advanced fibrosis can lead to cirrhosis, a condition in which the liver becomes so severely damaged that patients may require a transplant. There is no effective treatment, and patients urgently need new medications. Scientists believe one may emerge from the fascinating discovery that a protein called TGF-beta 1 triggers liver inflammation and that blocking the protein may help. The researchers designed 10 chemically synthesized substances, termed siRNAs, with the ability to block or "silence" the TGF-beta 1 gene in the liver. When put into rat liver cells, the "gene silencers" decreased levels of type 1 collagen whose excessive production leads to fibrosis, as well as two other substances known to trigger liver inflammation, by almost 50 percent. The results suggest that gene silencing may be "an efficient and more specific approach for therapy of liver fibrosis," the report states. American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009